Dr. Antonarakis is a Professor of Oncology and Urology with an interest in genitourinary cancers and a particular focus on prostate cancer. He is an expert in the clinical management of patients with prostate cancer and other urological malignancies.
His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer, and using cancer genomics to inform precision oncology approaches. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 biomarker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 220 peer-reviewed articles, and several book chapters.
Clinical Trial Keywords
Phase II and III clinical trials in prostate cancer
View all on PubMed
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028-1038.
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015; 1: 582-591.
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017; 35: 2149-2156.
Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein J, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018; 74: 218-225.
Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019; 75: 378-382.
Multiple novel androgen receptor variants as biomarkers and therapeutic targets for androgen-refractory human prostate cancer
Patent # C10305 |
Methods and compositions related to prostate cancer therapeutics
Patent # C13126 |